Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS4 | Q9NRS4 | 11/20 | 0.65 |
| ▸ | P2RX1 | P51575 | 9/20 | 0.65 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.65 |
| ▸ | P2RX4 | Q99571 | 6/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | IKBKB | O14920 | 1/20 | 0.65 |
| ▸ | CHUK | O15111 | 1/20 | 0.65 |
| ▸ | KDR | P35968 | 1/20 | 0.65 |
| ▸ | FLT3 | P36888 | 1/20 | 0.65 |
| ▸ | MYLK | Q15746 | 1/20 | 0.65 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16707260 | 0.95 | TMPRSS4 (0.60) | TMPRSS4P2RX1P2RX7P2RX4MEN1 | |
| SCHEMBL3497425 | 0.89 | TMPRSS4 (0.64) | TMPRSS4P2RX1P2RX7P2RX4MEN1 | |
| SCHEMBL330156 | 0.89 | NR1H4 (0.60) | TMPRSS4P2RX1P2RX7P2RX4MEN1 | |
| SCHEMBL4498846 | 0.88 | TMPRSS4 (0.62) | TMPRSS4P2RX1P2RX7P2RX4MEN1 | |
| SCHEMBL3281999 | 0.88 | RHOC (0.56) | TMPRSS4P2RX1P2RX7P2RX4MEN1 | |
| SCHEMBL16709939 | 0.88 | TMPRSS4 (0.68) | TMPRSS4P2RX1P2RX7P2RX4MEN1 | |
| SCHEMBL16707252 | 0.86 | TMPRSS4 (0.67) | TMPRSS4P2RX1P2RX7P2RX4MEN1 | |
| SCHEMBL28870474 | 0.85 | P2RX1 (0.68) | TMPRSS4P2RX1P2RX7P2RX4MEN1 | |
| SCHEMBL330635 | 0.85 | TRPV1 (0.59) | TMPRSS4P2RX1P2RX7P2RX4MEN1 | |
| SCHEMBL19645367 | 0.84 | P2RX1 (0.67) | TMPRSS4P2RX1P2RX7P2RX4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503425-B2 | Methods of treating or controlling cytotoxic cerebral edema | AEROMICS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20240360077-A1 | METHODS | AEROMICS, INC. | 2024-10-31 | — | — | US | disclosed |
| US-11873266-B2 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | AEROMICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873266-B2 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | AEROMICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873266-B2 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | AEROMICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20220081391-A1 | METHODS | AEROMICS, INC. | 2022-03-17 | — | — | US | disclosed |
| CN-109512805-B | Compounds for the treatment of aquaporin mediated diseases | 埃罗米克斯公司 | 2021-12-31 | — | — | CN | disclosed |
| US-11084778-B2 | Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia | AEROMICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-11084778-B2 | Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia | AEROMICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20180334424-A1 | METHODS | AEROMICS, INC. | 2018-11-22 | — | — | US | disclosed |
| US-20100234452-A1 | Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders | GENMEDICA THERAPEUTICS SL (ES) | 2010-09-16 | — | — | US | disclosed |
| US-20090298923-A1 | Salicylate Conjugates Useful for Treating Metabolic Disorders | GENMEDICA THERAPEUTICS SL (ES) | 2009-12-03 | — | — | US | disclosed |
| WO-2009138437-A1 | SALICYLATE CONJUGATES USEFUL FOR TREATING METABOLIC DISORDERS | GENMEDICA THERAPEUTICS SL (ES) | 2009-11-19 | — | — | WO | disclosed |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-10-09 | — | — | US | disclosed |
| EP-1847263-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1844766-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234452-A1 | Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders | HSD17B14, SORD, GPX4 | TMPRSS4 1355/4885P2RX1 1580/4885P2RX7 1551/4885 |
| US-20180334424-A1 | METHODS | AQP4, AQP1, AQP3 | TMPRSS4 1257/4885P2RX1 2910/4885P2RX7 2817/4885 |
| US-20090298923-A1 | Salicylate Conjugates Useful for Treating Metabolic Disorders | HSD17B14, FAH, SORD | TMPRSS4 1412/4885P2RX1 2048/4885P2RX7 2098/4885 |
| US-12503425-B2 | Methods of treating or controlling cytotoxic cerebral edema | AQP4, AQP1, AQP3 | TMPRSS4 1043/4885P2RX1 2714/4885P2RX7 2687/4885 |
| US-20220081391-A1 | METHODS | AQP4, AQP1, AQP3 | TMPRSS4 1257/4885P2RX1 2910/4885P2RX7 2817/4885 |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | TMPRSS4 1647/4885P2RX1 1538/4885P2RX7 973/4885 |
| US-11084778-B2 | Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia | AQP4, AQP1, AQP3 | TMPRSS4 946/4885P2RX1 2805/4885P2RX7 2680/4885 |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | TMPRSS4 1647/4885P2RX1 1538/4885P2RX7 973/4885 |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | TMPRSS4 1647/4885P2RX1 1538/4885P2RX7 973/4885 |
| US-11873266-B2 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | AQP4, AQP1, AQP3 | TMPRSS4 1444/4885P2RX1 3317/4885P2RX7 3316/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | TMPRSS4 3292/4885P2RX1 2316/4885P2RX7 1605/4885 |
| US-20240360077-A1 | METHODS | AQP4, AQP1, AQP3 | TMPRSS4 1415/4885P2RX1 2797/4885P2RX7 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.